Long-Term Oncologic Outcomes After Radiofrequency Ablation for T1 Renal Cell Carcinoma
Long-Term Oncologic Outcomes After Radiofrequency Ablation for T1 Renal Cell Carcinoma
复制标题
DOI：
10.1016/j.eururo.2012.08.062
复制
发表时间：
2013-03-01
期刊：
影响因子：
23.4
通讯作者：
Gervais, Debra A.
中科院分区：
文献类型：
--
作者：
Psutka, Sarah P.;Feldman, Adam S.;Gervais, Debra A.
背景：肾细胞癌（RCC）的射频消融（RFA）用于获得小肾脏肿块的局部控制。然而，RFA 治疗 RCC 的长期肿瘤学结果受到数量少、随访时间短和缺乏病理诊断的限制。 目的：评估 RFA 治疗经活检证实的 RCC 的肿瘤学有效性。 设计、环境和参与者：排除标准包括既往 RCC 或转移性 RCC、家族综合征或 T2 RCC。我们回顾性评价了 185 名散发性 T1 肾细胞癌患者的长期肿瘤学结局。中位随访时间为 6.43 年（四分位距 [IQR]：5.3-7.7）。结果测量和统计分析：卡方检验和 Wilcoxon 秩和检验分别用于比较比例和中位数。使用Kaplan-Meier分析计算疾病特异性生存率和总生存率（OS），然后按肿瘤分期进行分层，并使用时序分析进行比较。报告了 5 年无病生存率 (DFS) 和 OS 率。 p值
Background: Radiofrequency ablation(RFA) of renal cell carcinoma(RCC) is used to obtain local control of small renal masses. However, available long-term oncologic outcomes for RFA of RCC are limited by small numbers, short follow-up, and lack of pathologic diagnoses.Objective: To assess the oncologic effectiveness of RFA for the treatment of biopsy-proven RCC.Design, setting, and participants: Exclusion criteria included prior RCC or metastatic RCC, familial syndromes, or T2 RCC. We retrospectively reviewed long-term oncologic outcomes for 185 patients with sporadic T1 RCC. Median follow-up was 6.43 yr (interquartile range [IQR]: 5.3-7.7).Outcome measurements and statistical analysis: The chi-square test and Wilcoxon rank-sum tests were used to compare proportions and medians, respectively. Disease-specific survival and overall survival (OS) were calculated using Kaplan-Meier analysis, then stratified by tumor stage, and comparisons were made using log-rank analysis. The 5-yr disease-free survival (DFS) and OS rates are reported. A p value